This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Acorda (ACOR) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Acorda (ACOR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Medicines Company (MDCO) Jumps: Stock Rises 5.5%
by Zacks Equity Research
Medicines Company (MDCO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Protalix Completes Enrollment in Third Fabry Disease Study
by Zacks Equity Research
Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
by Zacks Equity Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
Acceleron Discontinues Mid-Stage Muscular Dystrophy Study
by Zacks Equity Research
Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development.
Lexicon (LXRX) Catches Eye: Stock Jumps 7.3%
by Zacks Equity Research
Lexicon (LXRX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease
by Zacks Equity Research
The FDA grants orphan drug status to Akari's (AKTX) nomacopan for the treatment of bullous pemphigoid, a severe blistering skin condition.
Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study
by Zacks Equity Research
Celgene's (CELG) CC-486 maintenance therapy improves overall survival in newly-diagnosed acute myeloid leukemia patients.
Ligand (LGND) Surges: Stock Moves 6.3% Higher
by Zacks Equity Research
Ligand (LGND) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session
by Zacks Equity Research
Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
by Zacks Equity Research
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review
by Zacks Equity Research
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why
by Zacks Equity Research
Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.
Why Is Acorda (ACOR) Down 46.8% Since Last Earnings Report?
by Zacks Equity Research
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 7.5%
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Retrophin Down on Neurological Disorder Drug Study Failure
by Zacks Equity Research
Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.
Synlogic Discontinues Development of SYNB1020, Stock Down
by Zacks Equity Research
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Moderna (MRNA) Jumps: Stock Rises 5.6%
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.
Acorda Therapeutics Enters Oversold Territory
by Zacks Equity Research
Acorda Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD
by Zacks Equity Research
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Regeneron Ebola Treatment Shows Promise, Study Stopped Early
by Zacks Equity Research
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates
by Zacks Equity Research
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.